Number of participants with serious and non-serious adverse events 30 days [clinicaltrials_resource:3f289137a7682bea418555f484e9277b]

Number of participants with serious and non-serious adverse events 30 days [clinicaltrials_resource:3f289137a7682bea418555f484e9277b]

To determine the maximum tolerated and/or recommended dose of BPX-501 cells.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:3f289137a7682bea418555f484e9277b
Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant [clinicaltrials:NCT02065869]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Number of participants with serious and non-serious adverse events 30 days [clinicaltrials_resource:3f289137a7682bea418555f484e9277b]

To determine the maximum tolerated and/or recommended dose of BPX-501 cells.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:3f289137a7682bea418555f484e9277b
Bio2RDF identifier
3f289137a7682bea418555f484e9277b
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:3f289137a7682bea418555f484e9277b
measure [clinicaltrials_vocabulary:measure]
Number of participants with serious and non-serious adverse events
time frame [clinicaltrials_vocabulary:time-frame]
description
To determine the maximum tolerated and/or recommended dose of BPX-501 cells.
identifier
clinicaltrials_resource:3f289137a7682bea418555f484e9277b
title
Number of participants with serious and non-serious adverse events 30 days
@en
inDataset
type
label
Number of participants with se ...... 89137a7682bea418555f484e9277b]
@en